EADV24: Breakthrough in Early Melanoma Detection Using Tumour-Specific Antibodies
New research unveiled at the EADV Congress 2024 reveals a promising advancement in melanoma detection. This novel method utilises tumour-specific antibodies to identify early-stage melanoma, potentially revolutionising diagnosis and improving patient outcomes by detecting the disease at its most treatable stages.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
